

Listing and Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-8. (Cancelled)

9. (Currently amended) A method of killing cancer cells having a p53 mutation, said method comprising the separate, sequential or simultaneous administration to said cells of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed ~~a thymidylate synthase inhibitor~~.

10. (Currently amended) A method of treating cancer cells having a p53 mutation comprising the separate, sequential or simultaneous administration to a mammal in need thereof of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed ~~a thymidylate synthase inhibitor~~.

11. (Previously presented) The method according to claim 9 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

12. (Previously presented) The method according to claim 9 wherein the binding member is an antibody or a fragment thereof.

13. (Previously presented) The method according to claim 9 wherein the death receptor is FAS.

14. (Previously presented) The method according claim 9 wherein the binding member is the anti-FAS antibody CH11.
15. (Currently amended) The method according to claim 9 wherein said chemotherapeutic agent is ~~an antifolate thymidylate synthase inhibitor~~ or a topoisomerase-I inhibitor.
16. (Currently amended) The method according to claim 9 wherein said chemotherapeutic agent is ~~TDX~~ or irinotecan (CPT-11).
17. (Original) The method according to claim 16 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.
18. (Currently amended) A product comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, ~~as a combined preparation~~ for the simultaneous, separate or sequential administration of said specific binding member and said chemotherapeutic agent use in the treatment of cancer, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed ~~a thymidylate synthase inhibitor~~, and wherein the cancer cells comprise a p53 mutation.
19. (Currently amended) A pharmaceutical composition for the treatment of cancer characterised by the presence of a p53 mutation, wherein the composition comprises a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed ~~a thymidylate synthase inhibitor~~ and (c) a pharmaceutically acceptable excipient, diluent or carrier.

20. (Previously presented) The product according to claim 18 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer
21. (Previously presented) The product according to claim 18 wherein the binding member is an antibody or a fragment thereof.
22. (Previously presented) The product according to claim 18 wherein the death receptor is FAS.
23. (Previously presented) The product according to claim wherein the binding member is the anti-FAS antibody CH11.
24. (Currently amended) The product according to claim 18 wherein said chemotherapeutic agent is ~~an antifolate-thymidylate synthase inhibitor~~ or a topoisomerase-I inhibitor
25. (Currently amended) The product according to claim wherein said chemotherapeutic agent is ~~TDX or~~ irinotecan (CPT-11).
26. (Previously presented) The product according to claim 25 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.
27. (Currently amended) A kit for the treatment of a cancer characterised by the presence of a p53 mutation, said kit comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase I inhibitor or pemetrexed ~~a thymidylate synthase inhibitor~~ and (c) instructions for the administration of (a) and (b) separately, sequentially or simultaneously.

28. (Previously presented) The pharmaceutical composition according to claim 19 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.

29. (Previously presented) The pharmaceutical composition according to claim 19 wherein the binding member is an antibody or a fragment thereof.

30. (Previously presented) The pharmaceutical composition according to claim 19 wherein the death receptor is FAS.

31. (Previously presented) The pharmaceutical composition according to claim 19 wherein the binding member is the anti-FAS antibody CH11.

32. (Currently amended) The pharmaceutical composition according to claim 19 wherein said chemotherapeutic agent is ~~an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.~~

33. (Currently amended) The pharmaceutical composition according to claim 19 wherein said chemotherapeutic agent is ~~TDX~~ or irinotecan (CPT-11).

34. (Previously presented) The pharmaceutical composition according to claim 25 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.